MEDVi
Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Our Take
MEDVi carves out a niche by offering both oral and injectable compounded semaglutide — a combination most competitors don't provide. If you're needle-averse but want to eventually transition to injectables (which generally show better bioavailability), MEDVi lets you do that within one platform. The micro-dosing option is also thoughtful for patients with GI sensitivity concerns. At $179/mo, pricing is mid-range for compounded. The limitation is clear: compounded only, no insurance, and oral compounded semaglutide has less clinical validation than the injectable form. But for users who specifically want the oral-to-injectable flexibility, MEDVi is one of the best options.
What We Like
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
What Could Be Better
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Best For
Users who want a low entry price with oral and injectable compounded options
Alternatives to MEDVi
Similar providers by type, price, and features